Boyds’ CEO, Professor Alan Boyd, has been appointed as a Non-Executive Director at global pharmaceutical and services company, Clinigen Group.
Clinigen’s unique combination of businesses focus on providing ethical access to medicines, with its mission being to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Alan is currently working as a consultant for Clinigen, providing clinical and regulatory consultancy services in relation to its medical products.
With over 30 years of sector experience, Alan has held senior roles within Glaxo Group, ICI Pharma, Zenenca Pharmaceuticals and Ark Therapeutics. He is a graduate in Biochemistry and Medicine from the University of Birmingham and is a Fellow and the immediate past President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians. He is also a Fellow of the Royal College of Physicians, London and a Council Member of the Academy of Medical Royal Colleges.
Commenting on the appointment, Peter Allen, Chairman of Clinigen Group, said:
“On behalf of the Board, we are delighted to welcome Alan to the Group. He brings extensive industry experience and expertise in pharmaceutical services. His appointment strengthens the Board and will help to support and deliver the Group’s strategy. We are very much looking forward to working with Alan in his new NED capacity.”
Alan added:
“I am very pleased to be joining the Board at Clinigen Group and look forward to using my expertise to inform its strategy with the ultimate aim of advancing the development of pharmaceutical medicine for patient benefit.”
For more information about Clinigen, visit www.clinigengroup.com
